Fig. 2. Study scheme.
Study design showing the study population, randomization, and vaccination scheme. All subjects in per protocol analysis received two vaccinations at Day 1 and Day 29, received the challenge agent on day 57, with relevant blood draws for immunogenicity pre and post vaccination. D day, N number of participants. The syringe represents injection with 1790GAHB or placebo. The blood drop and gray container represent blood and stool samples, respectively.